Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 6/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9148661 | 0.82 | TLR4 (0.39) | MAPK1MCL1TLR4CYP1A2 | |
| SCHEMBL10192815 | 0.79 | ALDH1A1 (0.42) | MAPK1NPSR1CYP1A2 | |
| SCHEMBL535037 | 0.79 | MCL1 (0.42) | MAPK1MCL1TLR4CYP1A2RECQL | |
| SCHEMBL10534278 | 0.77 | TLR4 (0.64) | MAPK1TLR4NPSR1 | |
| SCHEMBL9146338 | 0.77 | MAPK1 (0.44) | MAPK1MCL1TLR4 | |
| SCHEMBL535116 | 0.76 | HSD17B10 (0.43) | MAPK1MCL1TLR4CYP1A2 | |
| SCHEMBL31276435 | 0.75 | MAPK1 (0.47) | MAPK1MCL1TLR4CYP1A2RECQL | |
| SCHEMBL21373971 | 0.75 | MCL1 (0.42) | MAPK1MCL1TLR4CYP1A2RECQL | |
| SCHEMBL374935 | 0.75 | MAPK1 (0.47) | MAPK1MCL1TLR4CYP1A2RECQL | |
| SCHEMBL28544847 | 0.75 | MCL1 (0.42) | MAPK1MCL1TLR4NPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158093-A1 | GPR 17 Agonists and Screening Assay | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158093-A1 | GPR 17 Agonists and Screening Assay | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158093-A1 | GPR 17 Agonists and Screening Assay | GPR27, GPR17, GPR65 | MAPK1 1893/4885MCL1 4579/4885TLR4 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.